Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes

References

• . Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997; 40(2):205–211
   PubMed Web of Science ®Google Scholar
• . Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet. 2002; 359(9309):824–830
   PubMed Web of Science ®Google Scholar
• . Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. J Biol Chem. 1992; 267(11):7402–7405
   PubMed Web of Science ®Google Scholar
• . Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008; 60(4):470–512
   PubMed Web of Science ®Google Scholar
• . Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: Beyond insulin and glucagon. Diabetes Spectrum. 2004; 17(2):183–190
   Google Scholar
• . Drucker D, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomized, open-label, non-inferiority study. Lancet. 2008; 372(9645):1240–1250
   PubMed Web of Science ®Google Scholar
• . Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Peptides. 2004; 117(2):77–88
   PubMedGoogle Scholar
• . Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2010. http://pi.lilly.com/us/byetta-pi.pdf. Accessed January 17, 2011
   Google Scholar
• . Fineman M, Flanagan S, Taylor K, . Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2010; 50(1):65–74
   Web of Science ®Google Scholar
• . Kim D, MacConell L, Zhuang D, . Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007; 30(6):1487–1493
   PubMed Web of Science ®Google Scholar
• . Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997; 28(1):5–24
   PubMed Web of Science ®Google Scholar
• . Swainston Harrison T, Plosker GL, Keam SJ. Extended-release intramuscular naltrexone. Drugs. 2006; 66(13):1741–1751
   PubMed Web of Science ®Google Scholar
• . Mannelli P, Peindl K, Masand PS, Patkar AA. Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Rev Neurother. 2007; 7(10):1265–1277
   PubMedGoogle Scholar
• . Risperdal Consta (risperidone) long-acting injection [package insert]. Wallingstown, Little Island, County Cork, Ireland: Janssen Pharmaceutical Ltd; Revised December 2010
   Google Scholar
• . Möller HJ. Long-acting injectable risperidone for the treatment of schizophrenia: Clinical perspectives. Drugs. 2007; 67(11):1541–1566
   PubMed Web of Science ®Google Scholar
• . Sandostatin LAR Depot [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009. http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_lar.pdf. Accessed April 29, 2011
   Google Scholar
• . Kolterman OG, Kim DD, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Syst Pharm. 2005; 62(2):173–181
   PubMed Web of Science ®Google Scholar
• . Blevins T, Pullman J, Malloy J, . DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011; 96(5):1301–1310
   PubMed Web of Science ®Google Scholar
• . Buse JB, Drucker DJ, Taylor KL, ; DURATION-1 Study Group. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010; 33(6):1255–1261
   PubMed Web of Science ®Google Scholar
• . Mazze R, Strock E, Morgan B, Wesley D, Bergenstal R, Cuddihy R. Diurnal glucose patterns of exenatide once weekly: A 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis. Endocr Pract. 2009; 15(4):326–334
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, . Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009; 32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract. 2009; 15(6):540–559
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. Curr Med Res Opin. 2008; 24(10):2943–2952
   PubMed Web of Science ®Google Scholar
• . Croom KF, McCormack PL. Liraglutide: A review of its use in type 2 diabetes mellitus. Drugs. 2009; 69(14):1985–2004
   PubMed Web of Science ®Google Scholar
• . Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010; 23(3):334–339
   PubMed Web of Science ®Google Scholar
• . Wu JD, Xu XH, Zhu J, . Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011; 13(2):143–148
   PubMed Web of Science ®Google Scholar
• . Derosa G, Maffioli P, Salvadeo SA, . Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther. 2010; 12(3):233–240
   PubMed Web of Science ®Google Scholar
• . Bunck MC, Diamant M, Eliasson B, . Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010; 33(8):1734–1737
   PubMed Web of Science ®Google Scholar
• . Buse JB, Bergenstal RM, Glass LC, . Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2011; 154(2):103–112
   PubMed Web of Science ®Google Scholar
• . Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23(8):1297–1310
   Web of Science ®Google Scholar
• . McDonald HG, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptitons. JAMA. 2002; 288(22): 2868–2879
   PubMed Web of Science ®Google Scholar
• . Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Prevalence and economic consequences of medication adherence in diabetes: A systematic literature review. Manag Care Interface. 2006; 19(7):31–41
   PubMedGoogle Scholar
• . Rubin R. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005; 118( suppl 5A):27S–34S
   PubMed Web of Science ®Google Scholar
• . Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med. 2009; 26(7):722–728
   PubMed Web of Science ®Google Scholar
• . Lorenzi G, Schreiner B, Osther J, Boardman M. Application of adult-learning principles to patient instructions: A usability study for an exenatide once-weekly injection device. Clin Diabetes. 2010; 28(4):157–162
   Google Scholar
• . Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010; 33:1759–1765
   PubMed Web of Science ®Google Scholar
• . Varanasi A, Chaudhuri A, Dhindsa S, . Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations. Endocr Pract. 2011; 17(2):192–200
   PubMed Web of Science ®Google Scholar
• . McAdam-Marx C, Ye X, Brixner DI, . A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab. 2009; 11(12): 1173–1174
   PubMed Web of Science ®Google Scholar
• . DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(d,-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes [published online ahead of print July 13, 2011]. Diabetes Technol Ther.
   Google Scholar
• . Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: An integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011; 10:22
   PubMed Web of Science ®Google Scholar
• . Linnebjerg H, Seger M, Kothare PA, Hunt T, Wolka AM, Mitchell MI. A thorough QT study to evaluate the effects of single-dose exenatide 10 μg on cardiac repolarization in healthy subjects. Int J Clin Pharmacol Ther. 2011; 49(2):99–108
   PubMed Web of Science ®Google Scholar
• . Sager P, Darpö B, Han J, . Exenatide once weekly did not affect corrected QT interval in patients with type 2 diabetes. Diabetes. 2011; 60( suppl 1):A294. Abstract 1070-P
   Web of Science ®Google Scholar
• . Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009; 25(4):1019–1027
   PubMed Web of Science ®Google Scholar
• . Dore DD, Bloomgren GL, Wenten M, . A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab. 2011; 13(6):559–566
   PubMed Web of Science ®Google Scholar
• . Mayo Clinic. Pancreatitis: causes. http://www.mayoclinic.com/health/pancreatitis/DS00371/DSECTION=causes. Accessed June 29, 2011
   Google Scholar
• . Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study. Diabetes Care. 2009; 32(5):834–838
   PubMed Web of Science ®Google Scholar
• . Knudsen LB, Madsen LW, Andersen S, . Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010; 151(4): 1473–1486
   PubMed Web of Science ®Google Scholar
• . Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care. 2003; 26(3):881–885
   PubMed Web of Science ®Google Scholar